BCRX on Nasdaq

BioCryst Pharmaceuticals

Logo: BioCryst Pharmaceuticals, Public domain, via Wikimedia Commons⁴

American pharmaceutical company

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

1986Founded¹

Compare with Repligen, Novavax or Bio-Techne, or pick any stock.

TickerBCRX on Nasdaq¹
Industrypharmaceutical industry¹
HeadquartersDurham¹
Websitewww.biocryst.com
Legal formDelaware corporation¹
Incorporated inDE⁵
Business address4505 Emperor Boulevard, Suite 200, Durham, Nc 27703⁵
Filer categoryLarge accelerated filer⁵

See how the biggest companies compare on our leaderboards

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

39.0%Operating margin⁷

30.2%Net margin⁷

94.1%Revenue growth, 2025⁷

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Orladeyo brought in 68% of the revenue BioCryst Pharmaceuticals broke down this way in fiscal 2025.

Orladeyo$601.8M⁷68%up 38% from 2024
License$244.0M⁷28%
Other Income From Contract With Customer$29.0M⁷3%up 122% from 2024
Collaborative And Other Research And Development$7.7M⁷1%down 4% from 2024

Products and services by year

Products and services	2023	2024	2025
Orladeyo	$326.0M	$437.7M	$601.8M
License	$0	$0	$244.0M
Other Income From Contract With Customer	$5.4M	$13.1M	$29.0M
Collaborative And Other Research And Development	$6.7M	$8.0M	$7.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and developmentSelling, general and adminProfit

Cost of revenue2¢$19.1M
Research and development19¢$166.1M
Selling, general and admin40¢$348.6M
Other costs8¢$73.6M
Income tax0¢$3.5M
Profit30¢$263.9M

Out of $874.8M in revenue.⁷

Where each dollar of operating cash went, fiscal 2025

Kept or used elsewhere

Kept or used elsewhere100¢$347.4M

Out of $347.4M of cash from operations.⁷

Financial statements

Revenue⁸⁹¹⁰¹¹⁷$874.8M in 2025+1691% since 2019

Operating income⁸⁹¹⁰¹¹⁷$341.0M in 2025

Net income⁸⁹¹⁰¹¹⁷$263.9M in 2025

Every line of the income statement in the latest annual report, as filed.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Total revenues	$874.8M	$450.7M	$331.4M
Cost of product sales	$19.1M	$12.3M	$4.5M
Research and development	$166.1M	$174.6M	$216.6M
Selling, general and administrative	$348.6M	$266.3M	$214.1M
Total operating expenses	$533.8M	$453.3M	$435.1M
Income (loss) from operations	$341.0M	-$2.5M	-$103.7M
Interest income	$10.7M	$14.7M	$15.8M
Interest expense	-$78.9M	-$98.5M	-$108.2M
Foreign currency losses, net	-$152.0K	-$641.0K	-$1.0M
Loss on extinguishment of debt	-$17.3M	$0	-$29.0M
Other income	$12.1M	$0	$0
Total other expense, net	-$73.6M	-$84.4M	-$122.5M
Income (loss) before income taxes	$267.4M	-$87.0M	-$226.2M
Income tax expense	$3.5M	$1.9M	$310.0K
Net income (loss)	$263.9M	-$88.9M	-$226.5M
Foreign currency translation adjustment	-$674.0K	-$776.0K	$180.0K
Unrealized (loss) gain on available for sale investments	-$209.0K	$360.0K	$1.1M
Total other comprehensive (loss) income	-$883.0K	-$416.0K	$1.3M
Net comprehensive income (loss)	$263.0M	-$89.3M	-$225.2M
Net income (loss) per common share: basic (in usd per share)	$1.26	-$0.43	-$1.18
Weighted average shares of common stock outstanding: basic (in shares)	209.9M shares	206.7M shares	192.2M shares
Net income (loss) per common share: diluted (in usd per share)	$1.21	-$0.43	-$1.18
Weighted average shares of common stock outstanding: diluted (in shares)	218.6M shares	206.7M shares	192.2M shares

Total assets¹⁴⁸⁹¹⁰¹¹⁷$514.2M in 2025+193% since 2019

Total liabilities¹¹⁷$633.3M in 2025−35% since 2023

Shareholders’ equity⁹¹⁰¹¹⁷-$119.2M in 2025

Cash¹⁴⁸⁹¹¹⁷$89.7M in 2025−21% since 2019

Long-term debt¹⁴⁸⁹¹⁰¹¹⁷$0 in 2025

Every line of the balance sheet in the latest annual report, as filed.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$89.7M	$104.7M	$110.6M
Restricted cash	$201.0K	$210.0K	$1.8M
Short-term investments	$185.0M	$216.1M
Trade receivables	$106.8M	$79.1M
Inventory, net	$5.4M	$8.1M
Prepaid expenses and other current assets	$17.2M	$13.8M
Total current assets	$404.3M	$422.0M
Long-term inventory, net	$24.0M	$23.2M
Property and equipment, net	$8.8M	$7.8M
Long-term investments	$61.2M	$20.3M
Right of use assets	$10.2M	$12.0M
Other assets	$5.7M	$5.2M
Total assets	$514.2M	$490.4M
Accounts payable	$15.8M	$11.6M
Accrued expenses	$126.4M	$113.3M
Share-based liability	$13.7M	$0
Operating lease liabilities	$317.0K	$937.0K
Finance lease liabilities	$1.3M	$1.8M
Royalty financing obligations	$38.5M	$32.7M
Total current liabilities	$196.1M	$160.4M
Operating lease liabilities	$8.6M	$7.9M
Finance lease liabilities	$1.4M	$2.1M
Royalty financing obligations	$427.2M	$481.1M
Secured term loan	$0	$314.9M
Total liabilities	$633.3M	$966.4M
Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at December 31, 2025 and 2024	$0	$0
Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding 213,060 and 208,543 at December 31, 2025 and 2024, respectively	$2.1M	$2.1M
Additional paid-in capital	$1.4B	$1.3B
Accumulated other comprehensive income	$38.0K	$921.0K
Accumulated deficit	-$1.5B	-$1.8B
Total stockholders deficit	-$119.2M	-$475.9M	-$455.5M
Total liabilities and stockholders deficit	$514.2M	$490.4M
Preferred stock, par or stated value (in usd per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	5.0M shares	5.0M shares
Preferred stock, shares issued (in shares)	0 shares	0 shares
Preferred stock, shares outstanding (in shares)	0 shares	0 shares
Common stock, par or stated value (in usd per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	450.0M shares	450.0M shares
Common stock, shares, issued (in shares)	213.1M shares	208.5M shares
Common stock, shares, outstanding (in shares)	213.1M shares	208.5M shares

Cash from operations⁸⁹¹⁰¹¹⁷$347.4M in 2025

Every line of the cash flow in the latest annual report, as filed.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income (loss)	$263.9M	-$88.9M	-$226.5M
Depreciation and amortization	$1.4M	$1.2M	$1.7M
Inventory obsolescence	$985.0K	$1.4M	$422.0K
Stock-based compensation expense	$85.1M	$65.4M	$55.6M
Equity modification associated with sale of BioCryst Ireland	$17.5M	$0	$0
Mark-to-market adjustment on share-based liability	-$4.3M	$0	$0
Payment of Pharmakon PIK Interest	-$23.7M	$0	$0
Non-cash interest expense on royalty financing obligations	$53.2M	$56.0M	$70.4M
Non-cash interest expense on secured term loan and amortization of debt issuance costs	$1.4M	$11.6M	$15.4M
Amortization of discount on investments, net	-$4.3M	-$11.5M	-$10.3M
Loss on extinguishment of debt	$17.3M	$0	$29.0M
Loss on impairment	$0	$0	$1.5M
Gain on sale of non-financial asset	-$550.0K	$0	$0
Gain on sale of BioCryst Ireland	-$3.6M	$0	$0
Increase in receivables	-$36.8M	-$22.7M	-$6.1M
Increase in inventory	-$1.6M	-$4.2M	-$1.4M
(Increase) decrease in prepaid expenses and other assets	-$7.8M	$2.0M	-$6.8M
Decrease in royalty financing obligations	-$68.4M	-$77.2M	-$29.3M
Increase in accounts payable and accrued expenses	$57.8M	$14.8M	$12.5M
Decrease in deferred revenue	$0	$0	-$1.2M
Net cash provided by (used in) operating activities	$347.4M	-$52.0M	-$95.1M
Acquisitions of property and equipment	-$2.5M	-$1.1M	-$2.2M
Purchases of investments	-$262.2M	-$266.8M	-$514.4M
Sales and maturities of investments	$256.6M	$320.5M	$385.1M
Sale of non-financial asset	$550.0K	$0	$0
Proceeds from sale of BioCryst Ireland, net of cash divested	-$6.2M	$0	$0
Net cash (used in) provided by investing activities	-$13.7M	$52.6M	-$131.5M
Net proceeds from common stock issued under stock-based compensation plans	$9.1M	$3.4M	$8.3M
Withholding taxes paid on stock-based awards	-$8.8M	-$7.5M	-$2.2M
Common stock issued to directors in lieu of cash retainer	$59.0K	$34.0K	$342.0K
Net proceeds from term loans	$0	$0	$300.0M
Repayment of principal on term loans	-$300.0M	$0	-$240.5M
Prepayment premium and fees on term loans	-$9.9M	$0	-$21.3M
Payment of debt issuance costs on Pharmakon Tranche A term loan	$0	$0	-$11.1M
Principal payments on royalty financing obligations	-$22.9M	$0	$0
Payment of royalty release fees	-$15.5M	$0	$0
Principal payments on finance lease liabilities	-$2.0M	-$1.7M	-$1.2M
Net cash (used in) provided by financing activities	-$349.9M	-$5.8M	$32.5M
Effect of exchange rates on cash, cash equivalents and restricted cash	$1.3M	-$936.0K	$362.0K
Decrease in cash, cash equivalents and restricted cash	-$15.0M	-$6.1M	-$193.8M
Cash paid for interest	$23.7M	$30.4M	$22.1M
Taxes withheld on stock-based awards included in accrued expenses	$132.0K	$758.0K	$4.2M
Capitalized software costs included in accrued expenses	$608.0K	$0	$0

Compare BioCryst Pharmaceuticals with another company

The story

The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.

From Wikipedia’s article on BioCryst Pharmaceuticals, shared under CC BY-SA 4.0.⁶

Timeline

1986Founded Founded¹

Recent filings

Sep 2, 20264 PRIMARY DOCUMENT
Sep 2, 20264 PRIMARY DOCUMENT
Sep 2, 20264 PRIMARY DOCUMENT
Sep 2, 20264 PRIMARY DOCUMENT
Sep 2, 20264 PRIMARY DOCUMENT
Aug 14, 2026SCHEDULE 13G/A
Aug 7, 2026SCHEDULE 13G
Aug 5, 20268-K
Aug 5, 202610-Q
Aug 5, 2026S-8
Aug 4, 20268-K/A
Jun 29, 20268-K
Jun 15, 20264 PRIMARY DOCUMENT
Jun 15, 20264 PRIMARY DOCUMENT
Jun 15, 20264 PRIMARY DOCUMENT

Every filing from the last three years, summarized. The full record is on SEC EDGAR.²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataBioCryst Pharmaceuticals on Wikidata
2
SEC EDGARBioCryst Pharmaceuticals filings on SEC EDGAR
3
WikipediaBioCryst Pharmaceuticals on Wikipedia
4
Wikimedia CommonsBioCryst Pharmaceuticals logo by BioCryst Pharmaceuticals, Public domain
5
SEC EDGARBioCryst Pharmaceuticals filings on SEC EDGAR
6
WikipediaBioCryst Pharmaceuticals on Wikipedia (revision used)
7
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2025
8
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2019
9
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2020
10
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2021
11
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2022
12
SEC EDGARBioCryst Pharmaceuticals 10-Q for fiscal 2026
13
SEC EDGARBioCryst Pharmaceuticals 10-Q for fiscal 2026
14
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2019
15
SEC EDGARBioCryst Pharmaceuticals 10-K for fiscal 2019